TD Asset Management Inc Has $36.26 Million Stake in Elanco Animal Health Incorporated $ELAN

TD Asset Management Inc lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 47.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,602,451 shares of the company’s stock after buying an additional 516,628 shares during the period. TD Asset Management Inc’s holdings in Elanco Animal Health were worth $36,263,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after buying an additional 759,623 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock worth $497,610,000 after buying an additional 1,962,276 shares during the period. UBS Group AG boosted its position in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Geode Capital Management LLC boosted its position in shares of Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock worth $213,343,000 after buying an additional 640,098 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $23.61 on Friday. The stock has a 50 day moving average price of $22.88 and a 200 day moving average price of $23.39. Elanco Animal Health Incorporated has a 52 week low of $13.15 and a 52 week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock has a market capitalization of $11.79 billion, a PE ratio of -47.22, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the prior year, the firm posted $0.37 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ELAN shares. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Citigroup upped their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, KeyCorp upped their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $28.20.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev A. Modi purchased 4,911 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.